First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer

The goal of this study is to identify a safe and tolerated dose of the orally administered KIF18A inhibitor ATX-295. In addition, this study will evaluate the pharmacokinetics, pharmacodynamics and preliminary antitumor activity of ATX-295 in patients with advanced solid tumors and ovarian cancer.

Trial Details

NCT ID
NCT06799065
Phase
PHASE1
Sponsor
Accent Therapeutics
Status
RECRUITING
Cancer Type
Triple Negative (TNBC) Breast Cancer
Interventions
  • ATX-295
Locations (sample)
  • Sarasota, Florida, United States|27.33643,-82.53065
  • Nashville, Tennessee, United States|36.16589,-86.78444
  • Houston, Texas, United States|29.76328,-95.36327
  • San Antonio, Texas, United States|29.42412,-98.49363
  • Fairfax, Virginia, United States|38.84622,-77.30637

Key Eligibility Criteria

  • Patients with histologically confirmed solid tumors who have locally recurrent or metastatic disease, including HGSOC
  • Refractory to or relapsed after all standard therapies with proven clinical benefit, unless as deemed by the Investigator, the subject is not a can…
  • For the expansion cohorts, participants must have histological confirmation of HGSOC and be determined to be platinum-resistant, platinum-refractor…
  • There is no limit to the number of prior treatment regimens

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Triple Negative (TNBC) Breast Cancer Trials on Trialify →